Compare Global X Defense Tech ETF (SHLD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs Zoetis Inc — how do they compare? Global X Defense Tech ETF trades at $70.68, while Zoetis Inc trades at $73.8 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Global X Defense Tech ETF pays none, and Global X Defense Tech ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| SHLD | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $156.76 |
52-Week Low | $58.20 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD (Global X Defense Tech ETF) trades at $70.15, up 0.43% with strong technical momentum as moving averages signal bullish alignment. The ETF benefits from increased institutional interest with multiple firms raising stakes in Q2 2026, while geopolitical tensions and rising global defense spending underpin sector tailwinds. However, key oscillators show neutral to overbought conditions with RSI levels above 78, suggesting potential near-term consolidation.
The defense technology sector outlook remains favorable amid elevated military budgets worldwide, though SHLD faces competition from similar ETFs and sensitivity to geopolitical developments. Current technical strength supports bullish momentum, but investors should monitor RSI levels for overextension risks amid evolving defense policy shifts.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
